GtoPdb Ligand ID: 9818

Synonyms: E 2609 | E-2609 | E2609
Compound class: Synthetic organic
Comment: BACE1 inhibitor for Alzheimer's disease jointly developed by Eisai and Biogen Inc. Phase 3 clinical study and FDA granted Fast Track designation. As of Feb 2018 no peer reviewed journal publications but structure identified in the patent [1].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 127.79
Molecular weight 437.11
XLogP 1.32
No. Lipinski's rules broken 0
Canonical SMILES CC1OCC2(C1CSC(=N2)N)c1cc(ccc1F)NC(=O)c1cnc(cn1)C(F)F
Isomeric SMILES C[C@H]1OC[C@]2([C@@H]1CSC(=N2)N)c1cc(ccc1F)NC(=O)c1cnc(cn1)C(F)F
InChI InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1
No information available.
Summary of Clinical Use
See NCT03036280 The trial, MissionAD2, is a 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with early Alzheimer's disease (EAD). It will include mild cognitive impairment (MCI) due to AD/prodromal AD and the early stages of mild AD and will be conducted to evaluate the efficacy and safety of elenbecestat.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03036280 A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_ Phase 3 Interventional Eisai Inc.